Skip to main content

Table 5 The Cumulative and Marginal Cost - Effectiveness and Cost – Benefit of SIF in Ottawa Using the Second Model

From: A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Ottawa, Canada

Variables

Annual cost of operation

Sharing rate

#of HIV averted

Cost-effectiveness ratio HIV

Benefit-cost ratio HIV

Post SIF

$2,182,800

11%

7

$311,829

0.68

 

($2,182,800)

 

(7)

($311,829)

(0.68)

Two SIF

$4,365,600

8%

13

$335,815

0.63

 

($2,182,800)

 

(6)

($363,800)

(0.6)

Three SIF

$6,548,400

6%

16

$409,275

0.51

 

($2,182,800)

 

(3)

($727,600)

(0.3)

Four SIF

$8,731,200

5%

18

$485,067

0.43

 

($2,182,800)

 

(2)

($1,091,400)

(0.19)

Five SIF

$10,914,000

3%

21

$519,714

0.4

 

($2,182,800)

 

(3)

($727,600)

(0.3)

Six SIF

$13,096,800

2%

24

$545,700

0.38

 

($2,182,800)

 

(3)

($727,600)

(0.3)

Seven SIF

$15,279,600

1%

27

$565,911

0.37

 

($2,182,800)

 

(3)

($727,600)

(0.3)

  1. Note: The numbers in parentheses represent the marginal results.